Analysts' Actions: BBRY WAG ADBE ZNGA SYMC

TheStreet Staff
March 20, 2013

NEW YORK ( TheStreet) -- CHANGE IN RATINGS

Research In Motion was upgraded at Morgan Stanley from underweight to overweight. $22 price target. Blackberry 10 should boost overall pricing and margins, Morgan Stanley said.

Walgreen was upgraded at JP Morgan to to overweight from neutral. $55 price target. Transforming the global supply chain with new strategic relationship, JP Morgan said.

Adobe Systems downgraded at Stifel from buy to hold. Stock appears fully valued at current levels, Stifel Nicolaus said.

Zynga downgraded at BofA Merrill to neutral from buy. $3.90 price target. Risk reward less compelling, Bank of America Merrill Lynch said.

Symantec downgraded at Oppenheimer from outperform to perform. Valuation call, as the stock is up 66% over the past 8 months, Oppenheimer said.

Cimarex Energy was downgraded at FBR from outperform to market pPerform. Valuation call, based on a $72 price target, FBR Capital Markets said.

Emergent BioSolutions was downgraded to hold at TheStreet Ratings.

AmerisourceBergen was upgraded at Citi to buy from neutral. The deal with Walgreens will be transformational, increasing international reach and adding purchasing power, said Citigroup. Price target is $62.

AmerisourceBergen was downgraded at ISI from buy to neutral. Valuation call, based on a $54 price target, ISI Group said.

Cardinal Health downgraded at Citi to neutral from buy. The loss of the contract with Walgreens will limit earnings growth, said Citigroup. Price target is $43.

Cardinal Health downgraded at ISI from strong buy to buy. $48.50 price target. Loss of WAG deal will cut into earnings, ISI Group said.

Ocwen was downgraded to hold at TheStreet Ratings.

VMware is rated new sector perform at FBN. $85 price target. Expect license growth to accelerate this year, FBN Securities said.

Cimarex Energy downgraded at FBR from outperform to market perform. Valuation call, based on a $72 price target, FBR Capital Markets said.

Williams Partners initiated at UBS with a neutral rating. While the company is a dominant midstream provider, commodity sensitivity remains, said UBS. Price target is $50.

STOCK COMMENTS/EPS CHANGES

Apple estimates, target cut at Canaccord Genuity. Shares are now seen reaching $600. Estimates were also reduced, as the iPhone could lose market share this year, according to Canaccord Genuity.. Buy rating.

Cobalt International price target increased at UBS to $36. The appraisal of the Shenandoah well was impressive and the North Platt oil pay was above pre-drill estimates, said UBS.

Salesforce.com rated new outperform at FBN. CRM was initiated with an outperform rating, FBN Securities said. $210 price target. Successfully growing shares in the SaaS market.

Marathon Oil price target increased at Citi. Based on a normalized valuation for a pure-play E&P company, the MRO price target was increased to $40, said Citigroup.

Adobe Systems price target and estimates increased at UBS through 2014. The migration to a subscription model continues to be better-than-expected, said UBS. New price target is $46.

Cardinal Health price target and estimates cut at UBS. The loss of the contract with Walgreens was disappointing and makes the CVS contract renewal even more important, said UBS. Price target goes to $50.

Crestwood Midstream estimates increased at UBS in 2014. The company is leveraging Enerven compression deal to further Marcellus build-out, benefiting 2014, said UBS.

The Hartford estimates increased at UBS. Price-to-book multiple expansion will continue with improvements in ROE and earnings mix shifts.

Microsoft estimates reduced at BMO through 2014. Company will be hurt by lower PC unit sales, BMO Capital said. Market perform rating and $30 price target.

Walgreens price target and estimates increased at UBS through 2014, said UBS. The deal with ABC will enhance EPS. Price target is now $51.

Williams-Sonoma estimates reduced at UBS on an outlook that was below consensus estimates. Operating margins will be flat to negative this year, said UBS.

Symantec price target increased at UBS to $28. Management's EPS growth outlook justifies a higher multiple, said UBS.

>To submit a news tip, email: tips@thestreet.com.

READERS ALSO LIKE:


Follow TheStreet on Twitter and become a fan on Facebook.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE.